Principles of cancer prevention

Seminars in Oncology Nursing

Volumn 21, Issue 4, 2005, Pages 229-235

  Meyskens Jr , Frank L ^a,b   Tully, Patricia ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 27744533793     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soncn.2005.06.002     Document Type: Article

References (35)

1. F.L. Meyskens Jr Strategies for prevention of cancer in humans Oncology 6 1992 16 24
2. P. Greenwald Cancer prevention clinical trials J Clin Oncol 20 suppl 18 2002 14S 22S
3. F.L. Meyskens Jr Cancer prevention M. Abeloff J. Armitage A. Lichter J. Niederhuber Clinical Oncology Ed 3. 2004 Churchill Livingstone New York 425 472
4. D. Sidransky Emerging molecular markers of cancer Nat Rev Cancer 2 2002 210 219
5. F.L. Meyskens Jr Biomarkers intermediate endpoints and cancer prevention J Natl Cancer Inst Monogr 13 1992 177 182
6. J.A. O'Shaughnessy, F.J. Kelloff, G.B. Godon Treatment and prevention of intraepithelial neoplasia An important target for accelerated new agent development Clin Cancer Res 8 2002 314 346
7. G.J. Kelloff, R.L. Schilsky, D.S. Alberts Colorectal adenomas A prototype for the use of surrogate endpoints in the development of cancer prevention drugs Clin Cancer Res 10 2004 3908 3918
8. J.S. Bertram, L.N. Kolonel, F.L. Meyskens Jr Rationale and strategies for chemoprevention of cancer in humans Cancer Res 47 1987 3012 3031
9. A. Ewart-Toland, A. Balmain The genetics of cancer susceptibility From mouse to man Toxicol Pathol 32 suppl 1 2004 26 30
10. E.R. Fearn, B. Vogelstein A genetic model for colorectal tumorigenesis Cell 61 1990 759 767
11. M. Labazi, A.C. Phillips Oncogenes as regulators of apoptosis Essays Biochem 39 2003 89 104
12. K.E. Greco, S. Mahon Common hereditary cancer syndromes Semin Oncol Nurs 20 2004 164 177
13. X. Wu, H. Zhao, R. Suk Genetic susceptibility to tobacco-related cancer Oncogene 23 2004 6500 6523
14. S.M. Lippman, T.L. Bassford, F.L. Meyskens Jr Quantitative assessment of cancer risk Texas Med 8 1990 48 53
15. S.M. Lippman, T.L. Bassford, F.L. Meyskens Jr A quantitatively scored cancer-risk assessment tool Its development and use J Cancer Educ 7 1992 15 36
16. B.C. Bastian Molecular genetics of melanocytic neoplasia practical applications for diagnosis Pathology 36 2004 458 461
17. A. Hochhaus Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST) Ann Hematol 83 suppl 2 2004 S65 S66
18. D. Schottenfeld, J.L. Beebe-Dimmer Advances in cancer epidemiology Understanding causal mechanisms and the evidence of implementing interventions Annu Rev Public Health 26 2005 37 60
19. D. Culler, S.J. Grimes, L.S. Acheson Cancer genetics in primary care Prim Care 31 2004 649 683
20. P. Jepsen, S.P. Johnsen, M.W. Gillman Interpretation of observational studies Heart 90 2004 956 960
21. A.J. Duffield-Lillico, E.H. Slate, M.E. Reid Nutritional Prevention of Cancer Study Group Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial J Natl Cancer Inst 95 2003 1477 1481
22. A.J. Duffield-Lillico, M.E. Reid, B.W. Turnbull Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial A summary report of the Nutritional Prevention of Cancer Trial Cancer Epidemiol Biomarkers Prev 11 2002 630 639
23. R.A. Smith, S.W. Duffy, R. Gabe The randomized trials of breast cancer screening What have we learned? Radiol Clin North Am 42 2004 793 806
24. J.E. Manson, J. Hsia, K.C. Johnson Women's Health Initiative Investigators Estrogen plus progestin and the risk of coronary heart disease N Engl J Med 349 2003 523 534
25. G.E. Goodman The clinical evaluation of cancer chemoprevention agents Defining and contrasting phase I, II, and III objectives Cancer Res 52 suppl 1992 2752s 2757s
26. F.L. Meyskens Jr, E. Szabo How should we move the filed of chemopreventive agent development forward in a productive manner? Recent Results Cancer Res 166 2005 113 124
27. W.B. Armstrong, T.H. Taylor, F.L. Meyskens Jr Can a marker be a surrogate for development of cancer, and would we know it if it exists? Recent Results Cancer Res 166 2005 99 112
28. D.F. Ransohoff Rules of evidence for cancer molecular-marker discovery and validation Nat Rev Cancer 4 2004 309 314
29. A. Schatzkin, M. Gail The promise and peril of surrogate and end points in cancer research Nat Rev Cancer 2 2002 19 27
30. W.K. Hong, S.M. Lippman, L.M. Itri Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck N Engl J Med 323 1990 795 801
31. B. Fisher, J.P. Constantino, D.L. Wickerham Tamoxifen for prevention of breast cancer Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 90 1998 1371 1388
32. J.L. Ramstack, S.E. White, K.S. Hazelkorn Sunshine and skin cancer A school-based skin cancer prevention project J Cancer Educ 1 1986 001 008
33. F.L. Meyskens Jr Screening for cancer Valuable or not? Curr Oncol Report 6 2004 485 490
34. F.L. Meyskens Jr Coming of age Chemoprevention of cancer N Engl J Med 323 1990 825 827
35. R.B. Harris, D.S. Alberts Strategies for skin cancer prevention Int J Dermatol 43 2004 243 251